Selenium overexposure induces insulin resistance: In silico study

Behar, Ammaria; Dennouni-Medjati, Nouria; Harek, Yahia; Dali-Sahi, Majda; Belhadj, Moussa; Meziane, Fatima Zahra

doi:10.1016/j.dsx.2020.08.005

Cited by 8 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beneficial effects and no adverse effects have also been reported against diabetes (132)(133)(134). However, high-level consumption could promote insulin resistance and should be avoided (135).…”

Section: Seleniummentioning

confidence: 99%

Integrative Management of Pancreatic Cancer (PDAC): Emerging Complementary Agents and Modalities

Djamgoz

Jentzsch

2021

Nutrition and Cancer

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. The standard first-line treatment for PDAC is gemcitabine chemotherapy which, unfortunately, offers only limited chance of a lasting cure. This review further evaluates the hypothesis that the effectiveness of gemcitabine can be improved by combining it with evidence-based complementary measures. Previously, supported by clinical trial data, we suggested that a number of dietary factors and nutraceuticals can be integrated with gemcitabine therapy. Here, we evaluate a further 10 agents for which no clinical trials have (yet) been carried out but there are promising data from in vivo and/or in vitro studies including experiments involving combined treatments with gemcitabine. Two groups of complementary agents are considered: Dietary factors (resveratrol, epigallocatechin gallate, vitamin B9, capsaicin, quercetin and sulforaphane) and nutraceutical agents (artemisinin, garcinol, thymoquinone and emodin). in addition, we identified seven promising agents for which there is currently only basic (mostly in vitro) data. Finally, as a special case of combination therapy, we highlighted synergistic drug combinations involving gemcitabine with "repurposed" aspirin or metformin. we conclude overall that integrated management of PDAC currently is likely to produce the best outcome for patients and for this a wide range of complementary measures is available.

show abstract